Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8528
Title: | Infliximab therapy for familial Mediterranean fever-related amyloidosis: Case series with long term follow-up | Authors: | Özçakar, Z.B. Yüksel, Selçuk Ekim, M. Yalçinkaya, F. |
Keywords: | Amyloidosis Familial Mediterranean fever Infliximab Pediatric adalimumab albumin amyloid A protein colchicine creatinine digoxin etanercept infliximab isoniazid phosphorus potassium recombinant interleukin 1 receptor blocking agent abdominal pain adolescent amyloidosis anaphylaxis appendix perforation arthralgia arthritis case report child clinical feature consciousness disorder diarrhea drug efficacy drug substitution drug withdrawal electrolyte disturbance face edema familial Mediterranean fever female fever follow up gastrointestinal biopsy gastrointestinal symptom heart amyloidosis hemodialysis hepatitis C hospitalization human human tissue hypoalbuminemia hypotension infection joint swelling kidney amyloidosis kidney biopsy kidney dysfunction kidney transplantation leg edema long term care male malnutrition medical literature nephrotic syndrome nutritional intolerance pallor priority journal proteinuria quality of life remission review school school child supplementation thorax pain total parenteral nutrition treatment outcome vomiting work resumption Adolescent Anti-Inflammatory Agents, Non-Steroidal Antibodies, Monoclonal Child Colchicine Drug Therapy, Combination Familial Mediterranean Fever Female Follow-Up Studies Gout Suppressants Humans Male Treatment Outcome |
Abstract: | Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent selflimited attacks of fever and polyserositis. Reactive amyloid A amyloidosis is the most devastating complication of FMF, and amyloidosis continues to occur in the colchicine era in untreated and noncompliant patients. Unfortunately, there is no proven effective treatment for established amyloidosis. In this report, we present four FMF-related amyloidosis patients that were treated with long term infliximab therapy with the longest duration of follow-up, together with the literature review. Infliximab was very effective in controlling gastrointestinal system findings and protracted arthritis, and it also had a favorable impact on the clinical findings of nephrotic syndrome in these patients. In conclusion, by controlling debilitating complaints of amyloidosis with infliximab, quality of life increases in these patients, and they get rid of recurrent hospitalizations and return to school or work. © Clinical Rheumatology 2012. | URI: | https://hdl.handle.net/11499/8528 https://doi.org/10.1007/s10067-012-2009-1 |
ISSN: | 0770-3198 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
31
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
28
checked on Nov 21, 2024
Page view(s)
42
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.